Özet:

Chronic myeloid leukemia (KML) is a chronic myeloproliferative disease characterized by Philadelphia (Ph) chromosome positive. It is the first selective thyrozine kinase inhibitor (TKI) targeting the BCR-ABL protein. Nilotinib and dasatinib are two-story thyrozine kinase inhibitors used in the treatment of imatinib-resistant KML. The frequent side effects of these thyroxine kinase inhibitors are myelosuppression, nausea, vomiting, diarrhea and grade 1-2 skin outbreaks. The likelihood of occurring grade 3-4 skin outbreak is 3–5%, while the likelihood of occurring grade 3-4 skin outbreak is <1%. The 50 year old female patient was diagnosed with a positive chronic phase of the ph chromosome caused by leukositosis and the imatinib treatment began. Treatment of the 3rd. In the month after the detection of swelled, swelled injury from the skin was carried out skin biopsy and medication eruption was assessed and imatinib treatment was interrupted, nilotinib 2*400 mg/day began. In the 3rd year of Nilotinib treatment, after the detection of hyperemic injury and swelling on the skin, the nilotinib treatment was reduced to a dose of 2*200 mg/day and local treatment was started. In the 8th year of treatment with Nilotinib, a patient with grade 3-4 skin outbreak was interrupted and systemic steroid was added. Due to the development of 3-4 degrees of eruption, nilotinib was not able to start again, and treatment was replaced with dasatinib. With TKI and grade 3-4 skin outbreak developing in our patient, close tracking continues in terms of whether or not the skin reaction will develop under dasatinib.

Anahtar Kelimeler: